The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology
| Autor: | A. Maller, Kathryn Y Bray, Julie A. Nettifee, R. L. Bergman, Aude Castel, Kristen M. Messenger, Peter J Early, Mark G. Papich, B. Pastina, R. J. Waldron, Karen R. Muñana |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Antimetabolites Antineoplastic 040301 veterinary sciences Injections Subcutaneous Population Pharmacology 030226 pharmacology & pharmacy 0403 veterinary science 03 medical and health sciences Dogs 0302 clinical medicine Pharmacokinetics Meningoencephalitis Prednisone Blood plasma medicine Animals Dog Diseases Encephalomyelitis education Volume of distribution education.field_of_study General Veterinary business.industry Cytarabine Half-life 04 agricultural and veterinary sciences Drug Combinations Etiology Female business Immunosuppressive Agents medicine.drug |
| Zdroj: | Journal of Veterinary Pharmacology and Therapeutics. 41:638-643 |
| ISSN: | 0140-7783 |
| DOI: | 10.1111/jvp.12667 |
| Popis: | The objective of this study was to describe the pharmacokinetics (PK) of cytarabine (CA) after subcutaneous (SC) administration to dogs with meningoencephalomyelitis of unknown etiology (MUE). Twelve dogs received a single SC dose of CA at 50 mg/m2 as part of treatment of MUE. A sparse sampling technique was used to collect four blood samples from each dog from 0 to 360 min after administration. All dogs were concurrently receiving prednisone (0.5-2 mg kg-1 day-1 ). Plasma CA concentrations were measured by HPLC, and pharmacokinetic parameters were estimated using nonlinear mixed-effects modeling (NLME). Plasma drug concentrations ranged from 0.05 to 2.8 μg/ml. The population estimate (CV%) for elimination half-life and Tmax of cytarabine in dogs was 1.09 (21.93) hr and 0.55 (51.03) hr, respectively. The volume of distribution per fraction absorbed was 976.31 (10.85%) ml/kg. Mean plasma concentration of CA for all dogs was above 1.0 μg/ml at the 30-, 60-, 90-, and 120-min time points. In this study, the pharmacokinetics of CA in dogs with MUE after a single 50 mg/m2 SC injection in dogs was similar to what has been previously reported in healthy beagles; there was moderate variability in the population estimates in this clinical population of dogs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text